153 related articles for article (PubMed ID: 34544691)
1. Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine neoplasms: a nested case-control study of the UK primary care population.
Liao W; Clift AK; Patone M; Coupland C; González-Izquierdo A; Pereira SP; Hippisley-Cox J
Br J Gen Pract; 2021 Nov; 71(712):e836-e845. PubMed ID: 34544691
[TBL] [Abstract][Full Text] [Related]
2. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer.
Keane MG; Horsfall L; Rait G; Pereira SP
BMJ Open; 2014 Nov; 4(11):e005720. PubMed ID: 25410605
[TBL] [Abstract][Full Text] [Related]
3. Complementary role of computed tomography texture analysis for differentiation of pancreatic ductal adenocarcinoma from pancreatic neuroendocrine tumors in the portal-venous enhancement phase.
Reinert CP; Baumgartner K; Hepp T; Bitzer M; Horger M
Abdom Radiol (NY); 2020 Mar; 45(3):750-758. PubMed ID: 31953587
[TBL] [Abstract][Full Text] [Related]
4. Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms.
Obazee O; Capurso G; Tavano F; Archibugi L; De Bonis A; Greenhalf W; Key T; Pasquali C; Milanetto AC; Hackert T; Fogar P; Liço V; Dervenis C; Lawlor RT; Landoni L; Gazouli M; Zambon CF; Funel N; Strobel O; Jamroziak K; Cantù C; Malecka-Panas E; Landi S; Neoptolemos JP; Basso D; Talar-Wojnarowska R; Rinzivillo M; Andriulli A; Canzian F; Campa D
Carcinogenesis; 2018 Mar; 39(3):360-367. PubMed ID: 29309705
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 and PTEN expression in pancreatic ductal adenocarcinoma, pancreatic neuroendocrine neoplasms and gastrointestinal tumors on fine-needle aspiration cytology.
Jiang K; Lawson D; Cohen C; Siddiqui MT
Acta Cytol; 2014; 58(3):281-7. PubMed ID: 24854395
[TBL] [Abstract][Full Text] [Related]
6. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
7. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study.
Lu L; Shang Y; Mullins CS; Zhang X; Linnebacher M
Future Oncol; 2021 Feb; 17(5):549-563. PubMed ID: 33401958
[No Abstract] [Full Text] [Related]
8. New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer.
Takikawa T; Kikuta K; Kume K; Hamada S; Miura S; Yoshida N; Hongo S; Tanaka Y; Matsumoto R; Sano T; Ikeda M; Iseki M; Unno M; Masamune A
Tohoku J Exp Med; 2020 Dec; 252(4):353-364. PubMed ID: 33342915
[TBL] [Abstract][Full Text] [Related]
9. Comparison of morphological features in lymph node metastasis between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinomas.
Takahashi D; Kojima M; Morisue R; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Ikeda M; Ochiai A
Pancreatology; 2020 Jul; 20(5):936-943. PubMed ID: 32553561
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients with undetected pancreatic cancer in primary care: an independent and external validation of QCancer(®) (Pancreas).
Collins GS; Altman DG
Br J Gen Pract; 2013 Sep; 63(614):e636-42. PubMed ID: 23998844
[TBL] [Abstract][Full Text] [Related]
11. Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case-control study.
Tan PS; Garriga C; Clift A; Liao W; Patone M; Coupland C; Bashford-Rogers R; Sivakumar S; Hippisley-Cox J
Gut; 2023 Mar; 72(3):512-521. PubMed ID: 35760494
[TBL] [Abstract][Full Text] [Related]
12. Sporadic pancreatic neuroendocrine neoplasms: A retrospective clinicopathological and outcome analysis from a Latvian study group.
Ptasnuka M; Truskovs A; Ozolins A; Narbuts Z; Sperga M; Plaudis H
Front Surg; 2023; 10():1131333. PubMed ID: 37021091
[TBL] [Abstract][Full Text] [Related]
13. Presentation and outcome of mixed neuroendocrine non-neuroendocrine neoplasms of the pancreas.
Nießen A; Schimmack S; Weber TF; Mayer P; Bergmann F; Hinz U; Büchler MW; Strobel O
Pancreatology; 2021 Jan; 21(1):224-235. PubMed ID: 33309225
[TBL] [Abstract][Full Text] [Related]
14. Weight Loss as an Untapped Early Detection Marker in Pancreatic and Periampullary Cancer.
Hue JJ; Sugumar K; Kyasaram RK; Shanahan J; Lyons J; Ocuin LM; Rothermel LD; Hardacre JM; Ammori JB; Rao G; Winter JM; Markt SC
Ann Surg Oncol; 2021 Oct; 28(11):6283-6292. PubMed ID: 33835301
[TBL] [Abstract][Full Text] [Related]
15. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: A nested case-control study in a Korean nationwide cohort.
Choi JH; Lee SH; Huh G; Chun JW; You MS; Paik WH; Ryu JK; Kim YT
Cancer Med; 2019 Dec; 8(17):7419-7430. PubMed ID: 31637875
[TBL] [Abstract][Full Text] [Related]
16. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
17. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-Control Study.
Toshima F; Watanabe R; Inoue D; Yoneda N; Yamamoto T; Sasahira N; Sasaki T; Matsuyama M; Minehiro K; Tateishi U; Gabata T
AJR Am J Roentgenol; 2021 Dec; 217(6):1353-1364. PubMed ID: 34161128
[No Abstract] [Full Text] [Related]
18. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
[TBL] [Abstract][Full Text] [Related]
19. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
20. The Evaluation of Gallstone Disease in the Year Before Pancreatic Cancer Diagnosis.
Papageorge MV; de Geus SWL; Woods AP; Ng SC; McAneny D; Tseng JF; Kenzik KM; Sachs TE
J Surg Res; 2023 Nov; 291():282-288. PubMed ID: 37481963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
